Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
EIF3J divergent transcript (also called EIF3J-AS1 or EIF3J antisense RNA 1) is a long non-coding RNA produced from the DNA sequence antisense to the protein-coding EIF3J gene. Unlike EIF3J itself—which encodes a core subunit of the eukaryotic initiation factor 3 complex (involved in translation initiation at ribosomes)[3]—EIF3J-DT is a regulatory transcript not known to directly encode a functional protein or serve as a druggable entity. No literature establishes its role as a receptor, enzyme, transporter, or therapeutic target or its involvement in disease or response to drugs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on EIF3J antisense RNA 1 (EIF3J-AS1).